Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approved. Investigators note prevalence of Candida infections in patients on the Novartis drug.

Advertisement

Related Content

IL-17: Pushing The Limits Of A Drug Target
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel